Provided by Tiger Trade Technology Pte. Ltd.

Fulcrum Therapeutics

3.84
+0.01000.26%
Volume:406.93K
Turnover:1.55M
Market Cap:292.98M
PE:-3.17
High:3.86
Open:3.84
Low:3.78
Close:3.83
52wk High:15.74
52wk Low:2.83
Shares:76.30M
Float Shares:63.49M
Volume Ratio:0.24
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2104
EPS(LYR):-1.1819
ROE:-32.38%
ROA:-19.59%
PB:0.94
PE(LYR):-3.25

Loading ...

Press Release: $hareholder Alert: the M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC

Dow Jones
·
Yesterday

U.S. Stocks on the MOVE - Sunrun, JetBlue Airways, Dell Technologies

Reuters
·
Aug 17

Unusually active option classes on open August 17th

TIPRANKS
·
Aug 17

U.S. Stocks on the MOVE - KBR, Vista Energy, Fulcrum Therapeutics

Reuters
·
Aug 17

Fulcrum Therapeutics, Slate Medicines to combine in an all-stock transaction

TIPRANKS
·
Aug 17

Fulcrum Therapeutics to Merge with Slate Medicines in All-Stock Deal

Reuters
·
Aug 17

Fulcrum Therapeutics, - Combined Company to Operate as Slate Medicines, Expected to Trade as 'Slte' on NASDAQ

THOMSON REUTERS
·
Aug 17

Fulcrum Therapeutics, - Slate Secures $245 Mln in Concurrent Private Placement

THOMSON REUTERS
·
Aug 17

Fulcrum Therapeutics, - Combined Company Cash Expected to Fund Slate's Operations into 2029

THOMSON REUTERS
·
Aug 17

Fulcrum Therapeutics, - to Contribute $20.30 Mln Net Cash and Pay $270 Mln Cash Dividend Pre-Merger

THOMSON REUTERS
·
Aug 17

Fulcrum Therapeutics, - Pre-Merger Fulcrum Stockholders to Own 5%, Slate Stockholders 95% of Combined Company

THOMSON REUTERS
·
Aug 17

Press Release: Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies

Dow Jones
·
Aug 17

Fulcrum CFO Alan Musso Takes over as Principal Accounting Officer After Tourangeau Exit

Reuters
·
Aug 10

Fulcrum Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Fulcrum Therapeutics 10% Owner Kevin Tang Acquires $594,132 of Common Shares

Reuters
·
Jul 21

Fulcrum Therapeutics 10% Owner Kevin Tang Reports Buying $892,170 of Common Shares

Reuters
·
Jul 16

Fulcrum Therapeutics Director Alan Ezekowitz Disposes of 18,000 Common Shares for $65,614

Reuters
·
Jul 01

Fulcrum Therapeutics Shareholders Reaffirm Board and Governance Structure

TIPRANKS
·
Jun 26

Fulcrum Therapeutics Shareholders Elect Banks, Ezekowitz, Hill as Directors

Reuters
·
Jun 26

Fulcrum Therapeutics Advances Restructuring with Leadership Changes

TIPRANKS
·
Jun 12